<DOC>
	<DOCNO>NCT00072839</DOCNO>
	<brief_summary>The purpose study determine whether investigational compound , ALX-0600 , safe effective treat Crohn 's Disease .</brief_summary>
	<brief_title>Safety Efficacy ALX-0600 Subjects With Active Crohn 's Disease</brief_title>
	<detailed_description>The study twelve week duration eight week once-daily injection abdomen thigh . There total six visit .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Inclusion Criteria 1 . Men woman , 18 year age old 2 . Signed date informed consent participate studyrelated procedure perform 3 . Diagnosis Crohn 's disease least 6 month document confirm 4 . A Crohn 's Disease Activity Index ( CDAI ) score 220 450 inclusive 5 . Female subject surgically sterile postmenopausal must use medically acceptable method birth control 30 day treatment period . 6 . HCT 30 % great 7 . WBC 3.5 x 109/L great 8 . Platelets 100 x 109/L great 9 . Adequate renal function define : serum creatinine BUN 1.5 x ULN less 10 . Adequate hepatic function define : ALT/SPGT , AST/SGOT 2.0 x ULN less ; total bilirubin 1.25 x ULN less , alkaline phosphatase 1.5 x ULN less 11 . Female subject childbearing potential must negative urine pregnancy test result prior randomization 12 . A stool sample must take screen analyzed local laboratory enteric pathogen , pathogenic ovum parasite , Clostridium difficile toxin , report negative prior randomization . 13 . Creactive protein value must 1.0 mg/dL , unless obvious manifestation currently active Crohn 's disease positive observation endoscopy , positive indication laboratory test result , subject previous intestinal resection Crohn 's disease . Exclusion Criteria 1 . Nutritionally compromised subject require enteral parenteral therapy maintain weight 2 . Body weight less 40 kg 100 kg 3 . Bowel obstruction condition may predispose development , intestinal perforation , significant gastrointestinal hemorrhage 4 . Current ileostomy colostomy extensive external fistulization ( 3 external fistula expressible gentle compression ) 5 . Expected require surgical therapy Crohn 's disease Crohn 's disease related complication within 12 week screen . If abscess present , drain least 3 week prescreening 6 . History ulcerative colitis within 6 month screen visit 7 . Cushing 's syndrome 8 . Known HIV infection , symptom sign HIV infection 9 . Acute systemic infection and/or intestinal infection require antibiotic therapy time screen baseline 10 . Evidence chronic hepatitis B C viral infection 11 . Decompensated liver disease 12 . Clinically significant ECG abnormalities 13 . History angina cardiac arrhythmia require drug device intervention clinically significant congestive heart failure clinically significant cardiac disease 14 . History myocardial infarction within 12 month screen 15 . History thromboembolic disease ( e.g. , phlebitis , pulmonary embolus ) know congenitally acquire prothrombotic disorder ( e.g. , protein C deficiency ) 16 . History cancer ( resect cutaneous basal squamous cell carcinoma situ cervical cancer ) clinically significant lymphoproliferative disease few 5 year document diseasefree state 17 . Known substance abuse previous 2 year 18 . Nursing mother pregnant woman 19 . Use native GLP2 , growth hormone , growth factor within 3 month sign informed consent 20 . Use prior concomitant medication describe section 5.4 , except specify 21 . Known hypersensitivity active inactive constituent ALX0600</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>